Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANA BIOTECHNOLOGY, INC.

(SANA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Sana Biotechnology

09/13/2021 | 07:57am EDT


© MT Newswires 2021
All news about SANA BIOTECHNOLOGY, INC.
10/19SANA BIOTECHNOLOGY : Signs Deal For Nonexclusive Commercial Rights to Beam Therapeutics' C..
MT
10/19SANA BIOTECHNOLOGY : Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technol..
PU
10/19SANA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Other Events, Finan..
AQ
10/19BEAM THERAPEUTICS : Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Ge..
AQ
10/15ILLUMINA : Appoints Bob Ragusa as GRAIL's CEO
MT
09/17INSIDER SELL : Sana Biotechnology
MT
09/13SANA BIOTECHNOLOGY, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
09/13INSIDER SELL : Sana Biotechnology
MT
09/07Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Confe..
GL
09/07Top Premarket Decliners
MT
More news
Analyst Recommendations on SANA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -374 M - -
Net cash 2021 544 M - -
P/E ratio 2021 -9,46x
Yield 2021 -
Capitalization 3 599 M 3 599 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 321
Free-Float 87,8%
Chart SANA BIOTECHNOLOGY, INC.
Duration : Period :
Sana Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 19,92 $
Average target price 37,50 $
Spread / Average Target 88,3%
EPS Revisions
Managers and Directors
Steven D. Harr President, Chief Executive Officer & Director
Nathan Hardy Chief Financial Officer & Senior Vice President
Hans Edgar Bishop Chairman
Sunil Agarwal Chief Medical Officer, EVP & Head-Development
Stacey Ma EVP & Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
SANA BIOTECHNOLOGY, INC.0.00%3 538
MODERNA, INC.218.76%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.40.38%48 194
SEAGEN INC.-0.17%31 811
CELLTRION, INC.-39.42%25 446